title: Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring.
abstract: OBJECTIVE
  Despite the known significant drug-drug interaction between isavuconazole and tacrolimus, there are no recommendations on dose adjustment when these drugs are given concomitantly. We report on a patient with a mediastinal Aspergillus fumigatus infection resistant to posaconazole and describe how she was successfully managed with tacrolimus therapeutic drug-level monitoring.
  
  
  METHODS
  Our patient presented with a mediastial Aspergillus fumigatus infection, 2 years after lung transplantation. A. fumigatus was resistant to posaconazole, and the patient had intolerance to voriconazole shown by elevated transaminases. The patient was given isavuconazole with drug-level monitoring. She was managed successfully with no adverse events. Tacrolimus concentration continued to increase after more than 2 weeks of therapy and required a further reduction to 72% of the usual dose to maintain the target concentrations over a 8-week period.
  
  
  CONCLUSIONS
  When isavuconazole is given to patients on tacrolimus, the dose of the latter will need considerable reduction. We would suggest an initial 50% reduction and recommend close weekly monitoring of tacrolimus concentration. Further dose decreases of 25-50% may be required.
authors.affiliation: Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.
authors.forename: T
authors.initials: T
authors.lastname: Kim
authors.affiliation: Office of Safety and Epidemiology, US Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: T
authors.initials: T
authors.lastname: Jancel
authors.affiliation: Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.
authors.forename: P
authors.initials: P
authors.lastname: Kumar
authors.affiliation: Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
authors.forename: A F
authors.initials: AF
authors.lastname: Freeman
keywords: drug-drug interaction; new antifungal agent; therapeutic drug monitoring